Preliminary results in Duchenne muscular dystrophy trial indicate promise for allogeneic cardiosphere-derived cells

Capricor Therapeutics presented six month data from their allogeneic cell therapy at the 2017 Parent Project Muscular Dystrophy Annual Connect Conference.

Go to the profile of Freya Leask
Jul 05, 2017

In a poster presented at the 2017 Parent Project Muscular Dystrophy Annual Connect Conference (29 June–2 July, Chicago, IL, USA), Capricor Therapeutics (CA, USA) revealed encouraging six month results from their Phase I/II HOPE-Duchenne clinical trial of CAP-1002 to treat Duchenne muscular dystrophy.

In this first trial, CAP-1002 was evaluated in young men and boys that have Duchenne muscular dystrophy with significant cardiac involvement. Subjects received CAP-1002, allogeneic cardiosphere-derived cells, intravenously into all three coronary arteries. CAP-1002 was found to improve cardiac systolic wall thickening and improve Performance of Upper Limb (mid-level).

Subject to regulatory approval, Capricor expects to launch its’ next trial of CAP-1002 in the second half of 2017.

View the full poster here.


Go to the profile of Freya Leask

Freya Leask

Publisher, Future Science Group

I am the Publisher of RegMedNet, 3DMedNet, RxNet and The Evidence Base, here to help users make the most of the websites and build our expert communities. I am passionate about digital and STM publishing, social media and story-telling. Please get in touch if you have any queries or comments!

No comments yet.